Proactive - Interviews for investors

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has secured exclusive worldwide licensing rights to TNX-4900, a highly selective small-molecule Sigma-1 receptor (S1R) antagonist with demonstrated analgesic activity across multiple preclinical models of neuropathic pain. Lederman explained that Sigma-1 receptor antagonism has attracted growing scientific and clinical interest as a promising new class of non-opioid, non-addictive pain therapies. Tonix has leveraged computer-aided and artificial intelligence–driven drug design approaches to develop this next generation of selective S1R antagonists. TNX-4900 has demonstrated robust and durable pain-relief activity in several validated neuropathic pain models, alongside an encouraging preclinical safety profile. TNX-4900 emerged from a structure-based drug design program led by researchers at Rutgers University, which generated a series of potent and selective triazole-based Sigma-1 receptor antagonists. The compound binds to the human Sigma-1 receptor with nanomolar affinity (Ki = 7.5 nM), exhibits greater than 100-fold selectivity over the Sigma-2 receptor, and shows strong penetration of the blood–brain barrier. In addition, TNX-4900 demonstrates favorable pharmacokinetic characteristics, including attractive absorption, distribution, metabolism, and elimination (ADME) properties and an oral bioavailability of approximately 28%. These attributes support its potential suitability for chronic oral administration in pain indications. In preclinical models of both diabetic neuropathy and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and sustained reductions in pain-related behaviours following both acute and repeated dosing. Importantly, these analgesic effects were observed without evidence of tolerance development or motor impairment, key limitations associated with many existing pain therapies. Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies as part of an IND-enabling development program. According to Lederman, the company believes TNX-4900 represents a compelling opportunity to address a large unmet medical need with a differentiated, non-opioid therapeutic option for patients suffering from neuropathic pain. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #SethLederman #ChronicPain #TNX4900 #TONMYA #FibromyalgiaTreatment #NeuropathicPain #PostherpeticNeuralgia #FDAApproval #PharmaNews #ProactiveInvestors

Arrow Exploration CEO Marshall Abbott joined Steve Darling from Proactive to provide an operational update on activity at the Mateguafa Attic field, located on the Tapir Block in Colombia’s prolific Llanos Basin, where Arrow holds a 50% beneficial interest. The update highlighted the successful drilling, completion, and initial production performance of the Mateguafa HZ7 (M-HZ7) horizontal well. Abbott confirmed that the M-HZ7 well was spud on November 22, 2025, and reached its target depth on December 4, 2025. The well was drilled safely, on time, and on budget to a total measured depth of 14,253 feet, corresponding to a true vertical depth of 8,440 feet. During drilling, the well intersected multiple hydrocarbon-bearing intervals, reinforcing the prospectivity of the Mateguafa field. The company has now brought the M-HZ7 well onto production from the Carbonera C9 formation. The well includes approximately 4,053 feet of horizontal oil pay within a clean sandstone reservoir exhibiting strong reservoir characteristics, including an average porosity of 23% and high resistivity readings. Following perforation, an electric submersible pump (ESP) was installed to support production operations. In addition to the C9 interval, the well also encountered approximately 20 feet of net oil pay, on a true vertical depth basis, within the Carbonera C7 formation, providing further upside potential from stacked reservoirs in the field. The M-HZ7 well was initially placed on production at a heavily restricted setting, using a 25/128 choke and a pump frequency of 30 Hz. At these conservative conditions, the well is producing approximately 1,694 barrels of oil per day on a gross basis, or 847 barrels of oil per day net to Arrow. The produced oil has an API gravity of 30.6°, with a low water cut of approximately 4%, primarily attributed to completion fluids and minor formation water. Abbott noted that the well continues to clean up and that performance will be closely monitored as operating parameters are gradually optimized. Abbott also provided updates on the broader Mateguafa development program, including activity at the Mateguafa-6, Mateguafa-5, and Mateguafa-8 wells. Following the tie-in and production start-up of the M-8 well, Arrow plans to drill the Mateguafa-9 (M-9) well. This well is designed primarily as a delineation and water disposal well to support ongoing development across the Mateguafa area. The M-9 well will be the final well drilled under Arrow’s 2025 drilling program. It is planned as a large step-out well located outside the currently interpreted limits of the reservoir. While its primary purpose is water disposal, Abbott noted that the well could potentially become a producer if the reservoir extends beyond current seismic interpretations. After completing the M-9 well, Arrow intends to continue drilling additional horizontal and vertical development wells within the Mateguafa field before moving the rig to the Icaco prospect, where the company plans to drill its first exploration well at that location. #proactiveinvestors #arrowexplorationinc #aim #axl #tsxv #axl #ColombiaEnergy #MarshallAbbott #Q1Results #OilDrilling #EnergyInvestment #SeismicSurvey #WaterDisposal #PrepaymentDeal #ExplorationAndProduction #LlanosBasin #EnergySector #ProactiveInvestors

U.S. Gold Corp. Chairman Luke Norman joined Steve Darling from Proactive to provide an update on the company’s financing activities following the successful closing of a private placement that raised approximately $31.2 million in gross proceeds. The financing represents a significant step forward as the company advances toward development of its flagship CK Gold Project in Wyoming. Norman explained that the offering was priced based on the closing price of U.S. Gold’s common shares on Monday, December 15, 2025, which was $16.91 per share. The pricing reflects an approximate 4% discount to the market close, a structure designed to balance investor participation while minimizing dilution. The warrants issued in connection with the private placement are immediately exercisable and have a two-year term from the date of issuance, providing additional potential upside for participants. The company intends to deploy the net proceeds strategically across several priorities. A primary focus will be funding initial development costs at the CK Gold Project, which has now entered the final stage of its Definitive Feasibility Study (DFS). In addition, funds may be allocated toward potential land acquisitions, further exploration across the company’s property portfolio, and general working capital to support ongoing operations. Norman emphasized that U.S. Gold is moving “full steam ahead” with the CK Gold Project, highlighting that site preparation activities are already underway. As the DFS progresses toward completion, the company believes it is well positioned to transition from advanced study work into the early stages of project development. With a strengthened balance sheet and capital in place, U.S. Gold Corp. expects 2026 to be a pivotal year as it works to de-risk the CK Gold Project, advance permitting and development planning, and create long-term value for shareholders. #proactiveinvestors #usgoldcorp #nasdaq #usau #mining #gold #copper USGoldCorp, #Mining #CKGoldProject #MiningInvestment #GoldMining #FeasibilityStudy #PowerInfrastructure #ProjectFinancing #MiningDevelopment #GoldStocks #WyomingMining

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to provide an update on the company’s commercialisation progress, highlighting a major regulatory milestone for its THERMAL-XR® ENHANCE graphene coating product. GMG announced it has received and accepted the United States Environmental Protection Agency’s consent notice approval conditions under the Pre-Manufacture Notice (PMN) process, clearing an important step toward full market entry in the United States. The EPA consent notice represents a significant achievement for GMG, as the PMN program is designed to ensure the safety and environmental suitability of new chemical substances introduced into the U.S. market. With this approval milestone in place, THERMAL-XR® ENHANCE is positioned to offer meaningful energy savings and enhanced corrosion resistance for U.S. consumers and commercial users across a range of industrial and building applications. Nicol explained that, upon receipt of the fully signed consent notice from the EPA—expected early in the new year—the first commercial shipment of THERMAL-XR® ENHANCE will be sent to Nu-Calgon. The product will be distributed and resold under the name “Nu-Calgon CoolWorx® powered by GMG Graphene,” marking GMG’s initial commercial rollout of the technology in the U.S. market. Beyond coatings, Nicol also provided an update on GMG’s Graphene Aluminium-Ion (G+AI) Battery technology, which is being developed in collaboration with the University of Queensland under a Joint Development Agreement with Rio Tinto, one of the world’s largest mining and metals companies. The project is also supported by the Battery Innovation Center of Indiana in the United States, strengthening the development and validation framework for the technology. GMG reported that, at its current stage of development, the G+AI Battery demonstrates performance characteristics comparable to high-power Lithium Titanate Oxide (LTO) batteries, which typically sell at premium prices of up to US$1,500 per kilowatt-hour. Importantly, GMG believes its graphene-based battery can be manufactured at a substantially lower cost, enabling pricing below that of LTO batteries. In 2025, global sales of LTO batteries reached approximately US$5.6 billion, underscoring the scale of the addressable market. Looking ahead, GMG management believes continued optimization of the cathode, anode, electrolyte, and overall component weight could enable the G+AI Battery to achieve energy densities of more than 150 Wh/kg when charged in one hour, and over 75 Wh/kg with ultra-fast six-minute charging. The company sees these performance targets as key drivers for future commercial competitiveness across a wide range of global energy storage applications. #GrapheneManufacturingGroup #CraigNicol #THERMALXR #GLubricant #REACHapproval #HVACR #CleanTech #GrapheneTechnology #EnergyEfficiency #SustainableTech #NuCalgon #SprayAcademy #EPAapproval #EuropeanMarket #ProactiveInvestors

Medicus Pharma Chief Medical Officer Dr. Faisel Mehmud joined Steve Darling from Proactive to announce that the company has entered into a non-binding letter of intent with Reliant AI, a decision-intelligence company specializing in generative artificial intelligence for the life sciences. The proposed collaboration is focused on developing an AI-powered data analytics platform designed to enhance clinical trial execution through advanced, data-driven insights. Reliant AI is a privately held company founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, alongside life sciences expert Richard Schlegel. The company combines state-of-the-art machine learning techniques with deep biomedical expertise to automate data-intensive workflows across the life sciences, ranging from systematic literature reviews to commercial success prediction. Its platform is designed to enable biopharma teams to make faster, more informed, evidence-based decisions throughout the research and development lifecycle. Dr. Mehmud explained that the proposed platform would integrate Reliant AI’s proprietary generative AI technology with Medicus’ clinical, operational, and internal datasets. The goal is to strengthen data-driven decision-making across Medicus’ clinical pipeline, with a particular focus on improving trial efficiency. Key anticipated capabilities include dynamic clinical-site selection, enhanced patient stratification, and more accurate enrollment forecasting. The initial phase of the collaboration is expected to focus on dynamic site selection supported by targeted patient-stratification analyses for an upcoming Teverelix clinical study, which is planned to begin in 2026. Subject to the execution of definitive agreements, Medicus expects the data analytics platform to be deployed initially in support of a Medicus-sponsored study during the Q2 to Q4 2026 period. There is also potential for the platform to be expanded to support a larger, late-stage clinical study planned for 2028, potentially in collaboration with a development or commercial partner. Medicus Pharma is currently advancing its SKNJCT-003 Phase 2 clinical study, which is being conducted across nine clinical sites in the United States. The study, which began randomizing patients in August 2024, is a randomized, double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating a non-invasive treatment for basal cell carcinoma of the skin. The study uses Medicus’ novel, patent-protected, dissolvable doxorubicin-containing microneedle array (D-MNA) technology, highlighting the company’s broader commitment to innovation in both therapeutic development and clinical execution. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce that the company has successfully completed its due diligence process and is preparing to close its acquisition of Krafty Labs on January 2, 2026, subject to customary closing conditions, including approval from the Canadian Securities Exchange (CSE). Gappelberg explained that Krafty Labs brings a highly attractive blue-chip customer roster that includes global technology and enterprise leaders such as Google, Microsoft, Netflix, Oracle, Yelp, ZoomInfo, Spotify, and Meta, among others. In addition to its strong customer base, Krafty Labs has generated approximately $1.2 million in year-to-date 2025 revenue, supported by robust gross margins of roughly 72%, underscoring the scalability and profitability of its platform. Management believes the acquisition will significantly enhance Nextech3D.ai’s AI-first event and engagement ecosystem by adding enterprise-grade capabilities that complement its existing technology stack. The integration of Krafty Labs’ advanced engagement tools with Nextech3D.ai’s in-person, virtual, and hybrid event solutions is expected to expand the company’s reach into higher-value enterprise and association customers. Gappelberg noted that the combined platform is positioned to drive higher average contract values, foster deeper and longer-term customer relationships, and unlock new monetization opportunities across a broad range of event formats. By strengthening its foothold in the enterprise market, Nextech3D.ai aims to accelerate revenue growth while reinforcing its position as a leading provider of AI-powered event and experience technologies. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab

HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s imminent transition into helium production at its Rudyard project in Montana. Sears confirmed that the PSA compressor, described as the "long lead item," is now en route to site, marking the final step in completing the processing unit. “Once that is delivered and installed, we will be a helium producing company,” Sears told Proactive, emphasizing that all other infrastructure is already in place. The company expects only minor fine-tuning once all components are connected. He noted that despite the upcoming holiday season slowing some activity, HeLIX remains on track. Sears also discussed expanded acreage at Rudyard, which he said has revealed greater potential with each well drilled. HeLIX is waiting for a suitable weather window post-Christmas to continue drilling operations, which were recently delayed by severe weather conditions. On the commercial side, Sears said discussions remain active around helium offtake agreements and potential hydrogen-related partnerships. However, final commitments will only follow first production. “It's just going to take a few days to get this thing plumbed together and in operation mode,” Sears added. “We are really excited about our future here.” Visit Proactive’s YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and turn on notifications so you don’t miss future content. #HeliumProduction #HeLIXExploration #MontanaEnergy #BoSears #RudyardProject #PSACompressor #EnergyStocks #HydrogenPartnerships #NaturalResources #ProactiveInvestors

Oakmount & Partners Ltd managing director Glenn King talked with Proactive's Stephen Gunnion about the progress investee company Intergroup Mining has made toward its planned listing on the Nasdaq stock exchange. King explained that the submission of legal and accounting documentation to the US Securities and Exchange Commission (SEC) marks a “significant milestone” for Intergroup Mining. “It now means that the company, from a tangible perspective, is just one stage closer to its debut listing,” he said. He noted that while the SEC now enters a review phase, Intergroup can respond to any questions and continue progressing toward its IPO. King also outlined the key compliance steps remaining and highlighted the importance of demonstrating strong financials, clear business plans, and limited share dilution. From an investor perspective, King said a US listing would deliver strategic benefits. “You’re on a notable tier one exchange with deep pools of liquidity,” he noted, adding that it may also position Intergroup as an acquisition target in the coming years. He added that Intergroup Mining produces kaolin, metakaolin, and is also positioned to begin gold production, noting that the project is considered a "legacy mine" with a life expectancy of more than 100 years. Updates are expected around late January or early February, depending on SEC feedback. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #IntergroupMining #NasdaqIPO #OakmountPartners #MiningStocks #Kaolin #GoldMining #Metakaolin #USListing #SECfiling #InvestorUpdates #IPOProcess #CapitalMarkets #ProactiveInvestors

Dekiln CEO Dr Aled Roberts talked with Proactive's Stephen Gunnion about the company’s breakthrough in sustainable ceramic tile production and how £3 million in funding from the Royal Academy of Engineering’s Green Future Fellowship program will help scale the technology. Roberts explained that conventional ceramic tiles have a high carbon footprint due to the energy-intensive kiln-firing process. Dekiln has developed an alternative by mimicking natural processes seen in seashells and tooth enamel, creating tiles that function and feel like ceramics without requiring high-temperature firing. “Our materials are made with very high recycled content,” said Roberts. The tiles are manufactured using recycled gypsum, plastics, and calcium sulfate, combined with a bio-based active ingredient. This not only lowers energy input but significantly reduces carbon emissions in the manufacturing process. The funding will support Dekiln’s transition from lab-scale production—currently at one square metre of tiles per day—to commercial-scale manufacturing. The company has recently moved into a new facility and upgraded to an entry-level commercial press, representing the first step in its scale-up journey. It now aims to work with a UK-based industrial partner to build a pilot plant. For more insights into Dekiln’s progress and the Frontier IP Group, PLC (LSE:FIPP) innovative portfolio, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe, and enable notifications for updates on future interviews and company developments. #Dekiln #SustainableMaterials #GreenTechnology #NetZero #RoyalAcademyOfEngineering #ClimateTech #RecycledMaterials #CeramicInnovation #LowCarbon #Cleantech

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to provide an update on the company’s strategic initiatives, including progress on its merger with Volato and a new offtake agreement with Next-Gen. Rosende confirmed that the long-anticipated merger with Volato is moving forward after delays caused by a recent government shutdown. “We were able to push it out quickly,” he said, referencing the company’s SEC filing response. The shareholder meeting to approve the merger is scheduled for February 26th, 2026, with the company aiming to close the deal by the end of the first quarter. This milestone is expected to strengthen M2i Global’s software development capabilities, particularly in applications supporting critical mineral supply chains. The CEO also shared details about a new partnership with Next-Gen, which operates a proprietary cathode material process. The facility in Australia will be the first of its kind outside China, and M2i Global has secured an exclusive offtake agreement for the material, expected to begin delivery in approximately two years. Rosende described the development as “really exciting news that we’ll be able to bring that to the United States,” underscoring the strategic importance of securing a stable, non-China-based supply of cathode materials for the North American market. Looking ahead to 2026, Rosende emphasized Volato’s critical role in the company’s broader Critical Minerals Reserve project. Volato will provide software solutions for material tracking, inventory management, and integration with partner operations. A pilot program is planned to validate the technology, ensuring seamless coordination across the supply chain and providing real-time analytics for strategic decision-making. Rosende concluded that these developments position M2i Global to enhance its operational capabilities, secure critical supply sources, and expand its footprint in the rapidly growing market for advanced battery materials and critical minerals. #proactiveinvestors #m2iglobalinc #otcqb #mtwo #CriticalMinerals #SupplyChainSecurity #StrategicMinerals #USDefense #EconomicSecurity #BlockchainLogistics #CriticalMinerals #NevadaMining #parslee #volato #gallium

Replenish Nutrients CEO Neil Wiens joined Steve Darling to outline the company’s transition from development into full commercialization, highlighted by strategic licensing agreements and a significant partnership in the United States. Wiens described 2025 as a pivotal transformation year for Replenish Nutrients. During this period, the company successfully completed its proof-of-concept phase, finalized key intellectual property filings, and moved into commercial-scale operations. “We are physically into that next phase where the licensing deals are real,” Wiens said, emphasizing that the business is now executing on its commercialization strategy rather than preparing for it. A central focus of the discussion was Replenish Nutrients’ recently announced U.S. licensing agreement with Farmers Union Enterprises. The agreement provides the company with access to approximately 70 million acres of farmland, representing a substantial commercial opportunity. Wiens highlighted the favorable timing of the deal, noting its alignment with a newly announced US$700 million USDA regenerative agriculture program. He described the timing as “absolutely fantastic,” as policy support and grower interest in soil health solutions continue to accelerate. Operationally, Wiens confirmed that the company’s Minnesota-based production facility is on track to become operational by June. In parallel, Replenish Nutrients is actively engaged in discussions to expand its footprint into four additional U.S. states. Beyond North America, the company is also evaluating opportunities in Brazil, citing strong synergies in nutrient usage and alignment with its existing supply chain partner. Wiens reiterated that farmer return on investment remains the cornerstone of adoption. “If I can get soil health plus keep my yield the same or better and also start decreasing my fungicide and pesticide use – I win as a farmer,” he said, underscoring the value proposition Replenish aims to deliver to growers. Looking ahead to 2026, Replenish Nutrients plans to scale its global presence while maintaining its operational and corporate base in Canada, positioning the company to benefit from the growing global focus on regenerative agriculture and sustainable food production. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions #Agritech #FertilizerInnovation #MJAgSolutions #PelletFertilizer #ProbioticSoil #BeisekerFacility #CanadianAgriculture

ProPhase Labs CEO Ted Karkus joined Steve Darling from Proactive to announce that the company has entered into a non-binding Letter of Intent (LOI) regarding a proposed reverse merger transaction with Advanced Biological Laboratories (ABL), a European biotechnology and MedTech group. Under the proposed structure, Advanced Biological would become the majority owner of the combined public entity, while ProPhase’s existing operations would continue as sister companies to a newly formed U.S. subsidiary expected to remain under ProPhase’s current management team. Karkus emphasized that the transaction remains subject to the execution of definitive agreements, regulatory approvals, and board authorization. However, the parties have discussed a preliminary, non-binding valuation framework that could imply an enterprise value of up to approximately US$30 million for ProPhase’s legacy business. This framework is intended to provide a basis for ongoing negotiations rather than a final valuation. As outlined in the LOI, and subject to applicable law and final documentation, ProPhase Labs may declare a special cash dividend of up to US$10 million payable to shareholders of record on a date to be determined. Importantly, any such dividend would be distributed separately and would not be part of the merged operating company. In addition, all Crown Medical Collections receivables are expected to be carved out and retained exclusively for the benefit of current ProPhase shareholders, further preserving value for existing investors. Advanced Biological Laboratories would contribute its global biotechnology and MedTech infrastructure to the combined company, including advanced health data processing platforms, cloud-based computing capabilities, and access to international financing resources. The combination is intended to create a more diversified healthcare technology platform with expanded global reach, while allowing ProPhase to unlock value for shareholders through potential cash distributions and retained assets. #proactiveinvestors #prophaselabs #nasdaq #prph #biotech #genomics #genomesequencing #ProPhaseLabs #AdvancedBiologicalLaboratories #ReverseMerger #LOI #Biotechnology #MedTech #HealthcareTechnology #StrategicTransaction #ShareholderValue #SpecialDividend #NasdaqListed #GlobalHealthcare #HealthData #CloudComputing #LifeSciences #MergersAndAcquisitions

Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company’s strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis’ strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company’s proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth

Happy Creek Minerals CEO Steve Gray joined Steve Darling from Proactive to share details of the company’s latest assay results from its 2025 diamond drilling program at the Fox Tungsten Project in British Columbia. The recently completed program focused on expanding the known tungsten mineralization at the Ridley Creek (RC) and BN zones, two of the project’s most prospective target areas. During September and October, Happy Creek completed a total of 18 diamond core drill holes at the Fox Project, drilling an aggregate 2,176 metres. The primary objective of the program was to test extensions of known calc-silicate horizons that host tungsten mineralization and to better define the geometry and continuity of these zones beneath areas of limited surface exposure. Gray told Proactive that drilling at the Ridley Creek zone successfully confirmed strong continuity of the calc-silicate horizon and expanded the mineralized system to the southwest. Importantly, the mineralization remains clearly open to the west beneath Deception Mountain, highlighting significant potential for further resource growth. One of the standout results from the RC zone came from hole F25-13, which intersected 1.18 metres grading an impressive 6.83% WO₃ at a downhole depth of 31.2 metres. At the BN zone, drilling on the northwest side intersected multiple calc-silicate horizons, supporting a stacked-layer geological model. One of these mineralized horizons was intersected at a depth of approximately 200 metres below surface, indicating the system extends well beyond previously tested depths. Results from hole F25-16 included 1.00 metre grading 0.88% WO₃ from 105.0 metres downhole, as well as a deeper intercept of 1.65 metres grading 0.57% WO₃ from 218.3 metres downhole. According to Gray, the 2025 drilling program clearly demonstrates that the calc-silicate horizons and associated tungsten mineralization at both the RC and BN zones remain open to the west and north beneath Deception Mountain. The results also point to the potential for additional, yet-to-be-discovered horizons at depth, reinforcing the Fox Project’s upside as a growing tungsten system. Happy Creek plans to incorporate the new assay and geological data into its ongoing interpretation work as it evaluates next steps for further drilling and resource expansion at the Fox Tungsten Project. #proactiveinvestors #happycreekmineralsltd #tsxv #hpy #Tungsten #WO3 #CriticalMinerals #BritishColumbiaMining #DrillResults #DiamondDrilling #MineralExploration #ResourceExpansion #CalcSilicate #TungstenMining #StrategicMetals #ExplorationSuccess #MiningNews #ProactiveInvestors

Ilika CEO Graeme Purdy joined Steve Darling from Proactive to announce that the company has begun shipping prototype Stereax M300 solid-state batteries to customers, marking a significant commercial milestone for the business. The initial shipments represent the first delivery of the M300 product and will be allocated to the 21 customers that currently make up Ilika’s existing order book. Many of these customers have already evaluated earlier-generation Stereax batteries supplied from Ilika’s UK pilot production line, and the new prototype deliveries are intended to support further validation and system-level integration. In parallel, a portion of the initial M300 batches will be retained by Ilika for its extensive internal testing programme. This programme is designed to generate a broader and more robust body of performance data aligned with demanding use cases, particularly within active implantable medical devices. Purdy told Proactive that the potential applications for the Stereax M300 span a wide range of implantable and wearable medical technologies. These include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables, and ophthalmology devices. He explained that Stereax’s small footprint, combined with enhanced charging capability, makes it especially well suited for AIMDs. Key benefits of the Stereax technology include reduced surgical time, greater flexibility in placing implants closer to the point of therapy, long operational life, and the convenience of user recharging at home. In addition, the battery’s ability to support Bluetooth radio functionality opens the door to advanced connected medical applications. As part of the commercialization process, Ilika and its strategic manufacturing partner, Cirtec Medical Corp, will actively gather feedback from this initial customer group. The insights gained will be used to verify customer experience and performance expectations before scaling up production. This latest milestone advances the 10-year manufacturing agreement signed in August 2023, under which Cirtec Medical, a leading US-based medical device manufacturer, will produce Ilika’s full Stereax battery portfolio. The commencement of prototype shipments represents a key step toward broader commercial deployment of Ilika’s solid-state battery technology in medical markets. #proactiveinvestors #ilika #aim #ika #goliathautomatedline #SolidStateBatteries #Stereax #GoliathBattery #BatteryTech #GraemePurdy #EVBatteries #EnergyStorage #CirtecMedical #JaguarLandRover #UniversityOfOxford #ProactiveInvestors

Regan Capital CIO Skyler Weinand joined Steve Darling from Proactive to share news about the dynamics of the fixed income markets, interest rates, and mortgage-backed securities. Weinand outlined Regan Capital’s focus on U.S. mortgage-backed securities, noting the company manages around $3.6 billion across mutual funds, ETFs, and a UCITS ETF for non-U.S. investors. “Mortgages are about $13.5 trillion outstanding,” Weinand said, emphasizing the scale of the U.S. mortgage market and the challenges retail investors face accessing it directly. He discussed how recent Federal Reserve rate cuts have not lowered long-term interest rates. In fact, the yield on longer-term bonds and mortgage rates have increased. Weinand stated, “Mortgage rates are actually higher today than they were last September.” He cautioned that loose financial conditions, robust corporate balance sheets, and rising equity markets suggest rates could move higher, even if the Fed implements more cuts. He noted growing corporate debt issuance, with examples like Google’s 50-year bond at a 5.7% coupon. For investors, Weinand recommended focusing on short-duration and floating-rate securities, especially those backed by U.S. government guarantees, which can offer higher yields with lower volatility. #FixedIncome #InterestRates #MortgageBonds #SkylerWeinand #ReganCapital #BondMarket #ETFs #ShortDurationBonds #FederalReserve #FinancialMarkets #InvestmentStrategy #FloatingRate #ProactiveInvestors

Standard Uranium CEO Jon Bey joined Steve Darling from Proactive to discuss the company’s operational progress throughout 2025 and outline its strategic roadmap heading into 2026, highlighting a year marked by successful capital raising, advancing exploration programs, and the expansion of its joint venture portfolio. Bey noted that Standard Uranium raised nearly C$7.0 million during 2025, providing the financial foundation to advance multiple exploration initiatives across its project portfolio. A significant portion of that capital has been allocated to the Davidson River project, which is now fully funded and preparing for the largest drill program in the project’s history. Drilling at Davidson River is scheduled to begin in late May 2026 and is expected to be a major catalyst for the company. One of the year’s key developments was the return of 100% ownership of the Sun Dog project to Standard Uranium after joint venture partner Arrow Energy was unable to meet its funding commitments. Bey explained that this outcome has positioned the company to re-engage the market, confirming that multiple confidentiality agreements have already been signed with interested joint venture partners. Subject to final agreements, drilling at Sun Dog is expected to resume in late summer 2026. The company also continued to advance its project generator business model by securing new joint venture agreements. Standard Uranium entered into a partnership with Aventis on the Corvo project and a separate agreement with Collective Metals on the Rocas project. Both projects are on track to begin drilling in the first quarter of 2026, further diversifying the company’s near-term exploration pipeline. Looking ahead, Bey confirmed that Standard Uranium’s full management and technical team will attend the Vancouver Resource Investment Conference in January 2026. The company plans to meet with investors and stakeholders at the event to provide updates on its exploration plans and outline anticipated catalysts for the year ahead. #proactiveinvestors #standarduraniumltd #tsxv #stnd #otcqb #sttdf #mining #uranium #corvoproject #UraniumExploration #AthabascaBasin #DavidsonRiver #MiningInnovation #Geophysics #AmbientNoiseTomography #ResourceInvesting #FleetSpace #UraniumDiscovery #MiningNews

1911 Gold Corporation Chairman Gary O’Connor joined Steve Darling from Proactive to announce the start of a 2,200-metre diamond drilling program at the Ogama-Rockland gold deposit, located southeast of the company’s True North Gold Project. The program has already commenced, with one surface diamond drill rig mobilized to site. The drilling campaign is designed to support both resource expansion and confirmation, as the company continues to advance its understanding of the Ogama-Rockland deposit and its potential integration with existing infrastructure at True North. The Ogama-Rockland gold deposit currently hosts an NI 43-101 compliant inferred mineral resource of approximately 1.28 million tonnes grading 8.17 grams per tonne gold, containing an estimated 337,000 ounces of gold. O’Connor emphasized that the deposit’s high-grade nature and shallow mineralization make it an attractive near-term development opportunity. According to O’Connor, the planned eight drill holes will focus on confirming the updated geological model and testing extensions of high-grade, quartz-vein-hosted gold mineralization at relatively shallow depths. Drilling will target both down-dip and along-strike extensions of the main vein system, as well as newly identified parallel structures that emerged from recent relogging and resampling of historical drill core and updated geological modelling. In addition to expanding the resource base, the company plans to conduct metallurgical test work on drill core samples collected during the program. This testing will evaluate the suitability of processing material from Ogama-Rockland at the existing True North processing facility, potentially providing a streamlined development pathway and capital efficiencies. Following completion of the drill program and analysis of the results, 1911 Gold plans to deliver an updated underground mineral resource estimate in the first half of 2026. The company views this program as an important step in unlocking additional value at Ogama-Rockland while leveraging its established infrastructure at the broader True North project. #proactiveinvestors #1911goldcorporation #1911gold #tsxv #aumb #otcqx #aumbf #GoldExploration #MiningNews #TrueNorthGold #OgamaRockland #DrillingUpdate #PEA #ResourceUpdate #GoldMiningCanada #TSXV #JuniorMining

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s recent progress across its two lead drug candidates, Bezisterim and BIV201, as BioVie positions itself for multiple clinical and regulatory catalysts in 2026. Bezisterim, an anti-inflammatory compound that blocks tumor necrosis factor alpha (TNF-α), is being evaluated across several indications, including Parkinson’s disease, long COVID, and Alzheimer’s disease. Do highlighted that the compound has delivered encouraging signals in prior studies, including improvements in muscle control and cognitive function, as well as evidence suggesting a slowing of biological aging. Building on these results, BioVie has launched a new clinical trial enrolling 60 patients with earlier-stage Parkinson’s disease to evaluate Bezisterim as a standalone therapy. The goal of the study is to assess the drug’s potential disease-modifying effects when administered earlier in the disease course. Topline data from this trial are expected in April or May of 2026. In parallel, BioVie is advancing a separate, larger clinical program targeting long COVID. The company is conducting a 200-patient trial designed to evaluate Bezisterim’s ability to address persistent inflammatory mechanisms believed to drive many long COVID symptoms. Enrollment for this study is expected to be completed by February 2026. The trial is supported by a $13 million grant awarded to BioVie, underscoring the growing recognition of inflammation as a key contributor to long COVID. Do also provided an update on BioVie’s second lead candidate, BIV201, which is being developed to treat ascites associated with late-stage liver disease. The company’s Phase 2 trial of BIV201 was stopped early after interim data showed the drug reduced fluid accumulation by more than 50%, a clinically meaningful outcome in a difficult-to-treat patient population. Following discussions with the U.S. Food and Drug Administration, BioVie has now received feedback and authorization to advance BIV201 directly into a single Phase 3 clinical trial, streamlining the development pathway. Looking ahead, Do emphasized that BioVie expects 2026 to be a transformational year, with multiple clinical data readouts across programs and the potential initiation of a pivotal Phase 3 study. “2026 will be a big catalyst year for us,” he said, highlighting the breadth of opportunities across the company’s pipeline. proactiveinvestors #biovieince #nasdaq #bivi #alzheimersdisease #dementia #Alzheimers #Dementia #NeurodegenerativeDiseases #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #DementiaAwareness #ElderlyCare #Neuroscience #MemoryImprovement #AlzheimersResearch #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #AlzheimersSolution #Caregivers #HealthyAging #MentalHealth #MedicalResearch #DementiaPrevention #Neurology #WorldAlzheimersDay #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company’s Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This achievement follows the company’s December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer’s disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer’s treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer’s disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer’s disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation